Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Augmenting Mitochondria in Immune Cells for Improved Cancer Immunotherapy
US2025381273A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025381273-A1 |
| Application number | US-202318878307-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 28, 2023 |
| Priority date | Jun 28, 2022 |
| Publication date | Dec 18, 2025 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compositions and methods in the context of mitochondrial transfer. Disclosed herein are methods that enable the efficient transfer of mitochondria from a donor cell to a recipient cell. The mitochondria-augmented cells are useful in the treatment of diseases and disorders, such as cancer. The present invention also relates to the molecular machinery involved in mitochondrial transfer.
First claim
Opening claim text (preview).
1 . A method of augmenting mitochondria in mammalian CD8-positive T cells by culturing said CD8-positive T cells with mitochondria donor cells. 2 . The method according to claim 1 , wherein said mitochondria donor cell is a hematopoietic cell or a stem cell. 3 . The method according to claim 1 , wherein said mitochondria donor cell is a bone marrow stromal cell or a mesenchymal stem/stromal cell. 4 . The method according to claim 1 , wherein said mammalian CD8-positive T cells and/or said mitochondria donor cells are Talin-2 positive. 5 . The method according to claim 4 , wherein said mammalian CD8-positive T cells and/or said mitochondria donor cells are engineered to express Talin-2. 6 . The method according to claim 1 , wherein said mammalian CD8-positive T cells further comprises an antigen-specific receptor. 7 . The method according to any one of claim 6 , wherein said antigen-specific receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR). 8 . A mitochondria-augmented mammalian CD8-positive T cell obtained by the method of claim 1 . 9 . A mitochondria-augmented mammalian CD8-positive T cell. 10 . A mitochondria-augmented mammalian CD8-positive T cell according to claim 9 , wherein said mammalian CD8-positive T cells further comprises an antigen-specific receptor. 11 . A mitochondria-augmented mammalian CD8-positive T cell according to claim 10 , wherein said antigen-specific receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR). 12 . A method for treatment of cancer in a patient, said method comprising administering to the patient a mitochondria-augmented mammalian CD8-positive T cell according to claim 9 . 13 . The method of claim 12 , wherein said cancer is a solid cancer or a hematological cancer. 14 . A method for enhancing CD8-positive T cell antitumor immunity in a patient, said method comprising administering to the patient a mitochondria-augmented mammalian CD8-positive T cell according to claim 9 . 15 . The method according to claim 12 , wherein said treatment additionally comprises an immune checkpoint inhibitor. 16 . The method according to claim 14 , wherein said treatment additionally comprises an immune checkpoint inhibitor. 17 . A mitochondria-augmented mammalian CD8-positive T cell according to claim 8 , wherein said mammalian CD8-positive T cells further comprises an antigen-specific receptor. 18 . A mitochondria-augmented mammalian CD8-positive T cell according to claim 17 , wherein said antigen-specific receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR). 19 . A method for treatment of cancer in a patient, said method comprising administering to the patient a mitochondria-augmented mammalian CD8-positive T cell according to claim 8 . 20 . A method for enhancing CD8-positive T cell antitumor immunity in a patient, said method comprising administering to the patient a mitochondria-augmented mammalian CD8-positive T cell according to claim 8 .
Assignees
Inventors
Classifications
Genetically modified cells · CPC title
Bone marrow stromal cells; whole marrow · CPC title
T lymphocytes · CPC title
against the immunoglobulin superfamily · CPC title
Chimeric antigen receptors [CAR] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2025381273A1 cover?
- The present invention relates to compositions and methods in the context of mitochondrial transfer. Disclosed herein are methods that enable the efficient transfer of mitochondria from a donor cell to a recipient cell. The mitochondria-augmented cells are useful in the treatment of diseases and disorders, such as cancer. The present invention also relates to the molecular machinery involved in …
- Who is the assignee on this patent?
- Leibniz Inst Fuer Immuntherapie Lit, Brigham & Womens Hospital Inc, The Us Secretary Department Of Health
- What technology area does this patent fall under?
- Primary CPC classification A61K40/11. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Dec 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).